Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Melphalan Flufenamide,Dexamethasone

            Therapeutic Area: Oncology Product Name: Pepaxto

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 01, 2021

            Details:

            The HORIZON study, evaluating intravenous PEPAXTO in combination with dexamethasone, included heavily pre-treated patients with a poor prognosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paclitaxel,Carboplatin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Elevar Therapeutics

            Deal Size: $698.0 million Upfront Cash: $20.0 million

            Deal Type: Partnership April 21, 2020

            Details:

            The global strategic partnership deal is signed regarding the commercialization of Oasmia’s anticancer product Apealea®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paclitaxel

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Elevar Therapeutics

            Deal Size: Undisclosed Upfront Cash: $20.0 million

            Deal Type: Partnership March 26, 2020

            Details:

            The partnership between Oasmia and Elevar grants Elevar the exclusive right to commercialize Apealea®, in all global territories, except countries in which Oasmia and its partners are already present.